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Glycogen synthase kinase 3β (GSK3β) is a serine/threonine protein 
kinase involved in human cancers including glioblastoma. We have 
previously demonstrated that GSK3β inhibition enhances temozolo-
mide effect in glioma cells. In this report, we investigated the molecu-
lar mechanisms of sensitization of glioblastoma cells to temozolomide 
by GSK3β inhibition, focusing on O6-methylguanine DNA meth-
yltransferase (MGMT) gene silencing. Glioblastoma tissues from 
patients treated with the GSK3β-inhibiting drugs were subjected to 
immunohistochemistry and methylation-specific PCR assay. Human 
glioblastoma cell lines T98G, U138, U251 and U87 were treated with 
a small-molecule GSK3β inhibitor, AR-A014418 or GSK3β-specific 
small interfering RNA. The combined effect of temozolomide and 
AR-A014418 on cell proliferation was determined by AlamarBlue 
assay and an isobologram method. MGMT promoter methylation 
was estimated by methylation-specific PCR and MethyLight assay. 
MGMT gene expression was evaluated by real-time quantitative 
reverse transcriptase-PCR. c-Myc and DNA (cytosine-5)-methyl-
transferase 3A binding to the MGMT promoter was estimated by 
chromatin immunoprecipitation assay. GSK3β inhibition decreased 
phosphorylation of glycogen synthase and reduced MGMT expres-
sion and increased MGMT promoter methylation in clinical tumors. 
In glioblastoma cell lines, GSK3β inhibition decreased cell viability, 
enhanced temozolomide effect and downregulated MGMT expres-
sion with relevant changes in the methylation levels of the MGMT 
promoter. Here, we showed for the first time that c-Myc binds to the 
MGMT promoter with consequent recruitment of DNA (cytosine-
5)-methyltransferase 3A, regulating the levels of MGMT promoter 
methylation. The results of this study suggest that GSK3β inhibition 
enhances temozolomide effect by silencing MGMT expression via 
c-Myc-mediated promoter methylation.
Introduction
Glioblastoma (GBM) is the most frequent malignant tumor of the 
brain and is highly unresponsive to the currently available anticancer 
treatments. The proliferative and invasive activity of GBM (1) hin-
ders curable surgical intervention and makes GBM highly resistant to 
radiation and chemotherapy (2) with median patient survival showing 
little improvement over the past 30 years (3). Consequently, there is 
an urgent need to develop new treatment modalities represented by 
molecular target-directed therapies (4,5).
O6-methylguanine DNA methyltransferase (MGMT) promoter 
methylation is an independent favorable prognostic factor in patients 
with GBM (6). The levels of MGMT gene promoter methylation are 
associated with MGMT expression and are important in setting the 
transcriptional state of the MGMT promoter through changes in chro-
matin structure (7). Although the MGMT promoter is methylated only 
in 22% of GBM cases, methylation status of the promoter is impli-
cated in chemosensitivity to temozolomide (TMZ) (6). Therefore, 
patients with a methylated MGMT promoter may benefit from TMZ 
therapy (6).
Glycogen synthase kinase 3β (GSK3β) is a multifunctional pro-
tein kinase that regulates various cellular pathways depending on its 
substrates for phosphorylation (8). We have shown that deregulated 
GSK3β expression and activity maintains survival and proliferation 
and that GSK3β-specific inhibitors suppress survival and prolifera-
tion and induce apoptosis in human GBM cells (9,10). We have also 
demonstrated that GSK3β inhibition significantly sensitized GBM 
cell lines to TMZ (10). Based on our research, we are conducting 
clinical research for the therapeutic effect of GSK3β inhibition in 
recurrent GBM.
Here, we investigated the molecular mechanisms underlying a 
combined effect of GSK3β inhibition with TMZ, focusing on MGMT 
gene silencing and its causal relationship with c-Myc signaling, which 
is known to be upregulated by GSK3β inhibition (11,12). The results 
suggest that GSK3β inhibition enhances TMZ effect by decreasing 
MGMT expression via its c-Myc-mediated promoter methylation.
Material and methods
Clinical tumor samples and histological examination
In our institute, clinical research entitled ‘Chemotherapy for recurrent malignant 
glioma with combined usage of temozolomide and GSK3β-inhibiting drugs’ 
is ongoing under the approval by the Medical Ethics Committee of Kanazawa 
University Hospital (UMIN Clinical Trial Registry: UMIN000005111). Acco-
rding to the institutional review board-approved protocol, fresh GBM tissues 
were obtained at surgery and/or autopsy. The histological diagnosis of tumor 
was determined according to the revised World Health Organization criteria 
(13). In seven patients registered for the trial, autopsy was available for three 
patients with obtained informed consent from their families and was per-
formed 2 h after death. Patients 1 and 2 underwent administration of GSK3β-
inhibiting drugs until death with last administration within 8 h antemortem. 
One patient stopped GSK3β-inhibiting drugs 3 months prior to death. Patients 
1 and 3 died from cerebrospinal fluid dissemination of GBM. Histology did 
not differ between the primary tumor and the recurrent tumor obtained by 
autopsy. In patient 2, the primary brain stem tumor tissues obtained by needle 
biopsy were diagnosed with GBM. This patient died from enlargement of the 
brain stem lesion. The autopsy specimens showed the presence of GBM. All 
tumor samples obtained were fixed in neutral-buffered 10% formalin and were 
embedded in paraffin. The detailed information and outcome of this clinical 
research will be submitted elsewhere.
Immunohistochemistry
Immunohistochemistry was performed for the clinical tumor tissues as 
described previously  (14). Briefly, formalin-fixed and paraffin-embedded 
tissue blocks were sectioned (6 μm thick) onto slides and then deparaffinized. 
Sections were immunostained using an Envision+ Kit (Dako, Tokyo, Japan) 
with anti-glycogen synthase polyclonal antibody, anti-phospho-glycogen 
synthase polyclonal antibody specific to serine (S) 641-phosphorylated 
glycogen synthase (p-GSS641) and anti-MGMT antibody (Cell Signaling 
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Fig.  1. (A) The immunohistochemical localization of phosphorylated GS in tissues. a and b, patient 1; c and d, patient 2; a and c, primary tumor; b and d, 












Technology, Danvers, MA) using a 1:200 dilution. Sections were microwaved 
for 15 min in target retrieval solution (pH 9.0; Dako), blocked by incubation 
in 0.3% H2O2 solution in methanol for 20 min. Non-specific immunoreactions 
were blocked at room temperature for 30 min using a Protein-Block Kit 
(Dako). Slides were incubated with rabbit anti-p-GSS641 antibody, anti-
glycogen synthase antibody or rabbit anti-MGMT antibody overnight at 4°C, 
and they were washed and secondary antibody was applied for 30 min. Sections 
were exposed to diaminobenzidine peroxidase substrate (Funakoshi) for 3–5 
min and counterstained with Mayer’s hematoxylin. Non-immune rabbit IgG 
(Sigma–Aldrich, St Louis, MO) was used as a negative control.
DNA extraction
After microscopic observation of hematoxylin and eosin-stained sections by a 
neuropathologist (H.S.), DNA was extracted from the tumor areas of formalin-
fixed and paraffin-embedded tissue samples of patient 1 by using a QIAamp 
DNA Mini Kit™ (Qiagen, GmbH, Hilden, Germany). The amount of the sam-
ple obtained by needle biopsy in patient 2 was not enough for DNA extraction.
Cell cultures
Human GBM cell lines T98G, U138, U251 and U87 were obtained from the 
American Type Culture Collection (Manassas, VA). Cell lines were maintained 
in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine 
serum both from GIBCO (Grand Island, NY) at 37°C and 5% CO2.
Effects of GSK3β inhibitors on tumor cells
GBM cells were serum starved for 24 h and seeded in the cell proliferation assay 
format, as detailed elsewhere (15–17). Briefly, cells were seeded in 96-well 
plastic plates and treated with dimethyl sulfoxide (DMSO) as a vehicle control 
or with a small-molecule GSK3β inhibitor AR-A014418 (Sigma) dissolved in 
equivalent amount of DMSO at escalating final concentrations (5–80 µmol/l). 
Medium was replaced after 72 h of incubation in all treatment and control wells 
with the medium of the same formulation (containing the same final concentra-
tion of AR-A014418) (17). The proliferation assay was performed by adding 
AlamarBlue (AbD Serotec, Kidlington, UK) to the cells 144 h after cell seeding 
to assess proliferation according to the manufacturer’s protocol. Absorbance 
values were measured by spectrophotometry using a Microplate Reader Model 
550 (Bio-Rad, Hercules, CA) at 540 and 590 nm. The relative cell viability 
was determined by calculated values of the percent difference in reduction of 
AlamarBlue between treated and control cells as described in the manufactur-
er’s protocol. The experiments were carried out in sextuplicates.
RNA interference
GBM cells seeded into 96-well plates were transfected with small inter-
fering RNA (siRNA) specific to human GSK3β (target sequence, 
5′-GCUCCAGAUCAUGAGAAAGCUAGAU-3′) proved to be effective in 
glioma cells in our previous study (10) or negative control siRNA (Stealth 
RNAi Negative Control Low GC duplex) both from Invitrogen (Grand Island, 
NY), or β-catenin-specific siRNA (Cell Signaling Technology). Lipofectamine 
RNAiMAX (Invitrogen) was used for transfection according to the manufac-
turer’s protocol. The relative cell viability was determined 72 h after incubation 
by the AlamarBlue assay.
Western blot analysis
Western blot analysis was performed on polyvinylidene difluoride membrane 
(Invitrogen), according to the standard procedure as described previously 
(14,16). Rabbit monoclonal anti-c-Myc antibody (Epitomics, Burlingame, 
CA), mouse monoclonal anti-GSK3β antibody and mouse monoclonal anti-
tyrosine 216-phosphorylated GSK3β antibody (BD Biosciences, San Jose, 
CA), anti-DNA (cytosine-5)-methyltransferase 3A antibody (Imgenex, San 
Diego, CA), anti-β-catenin antibody and anti-MGMT antibody (Cell Signaling 
Technology) were used at a dilution of 1:5000, 1:10 000, 1:5000, 1:1000, 
1:5000 and 1:2500, respectively.
Effect of GSK3β inhibition on the sensitivity of GBM cells to TMZ
After serum starvation for 24 h, GBM cells were seeded in the cell prolifera-
tion assay format. The cells were treated with DMSO (vehicle control), with 
escalating concentrations (50, 100, 200 and 400 μmol/l) of TMZ (Sigma), 
AR-A014418 (5, 10 and 20 μmol/l) or the combinations of indicated concen-
trations of TMZ and AR-A014418 dissolved in equivalent amount of DMSO. 
After treatment for 144 h, cells were subjected to the AlamarBlue assay to 
determine the dose-dependent effect and IC50 of TMZ and AR-A014418 
against GBM cells and to observe the influence of AR-A014418 (5, 10 or 
20 μmol/l) on TMZ effect against GBM cells. The influence of GSK3β inhibi-
tion on TMZ effect against GBM cells was analyzed using classic isobolo-
gram method (18) and median dose-effect analysis (19,20). The IC50 values 
and combination indices of the combination therapy by various concentrations 
of TMZ and AR-A014418 were plotted to determine whether the effect of 
GSK3β inhibitor on GBM cell sensitivity to TMZ was additive, synergistic 
or antagonistic.
Methylation-specific PCR assay
Isolated effect of GSK3β inhibition and combined influence of GSK3β 
and c-Myc inhibition on methylation status of the MGMT promoter were 
evaluated by methylation-specific PCR (MSP) assay as described previously 
(21,22). T98G, U251 and U138 cells were serum starved for 24 h and then 
treated with DMSO (control) or AR-A014418 (5, 10 or 20 μmol/l) or com-
bination of DMSO–AR-A014418 (5, 10 or 20 μmol/l) and c-Myc inhibitor 
20 μmol/l (EMD Millipore, Billerica, MA) dissolved in equivalent amount 
of DMSO. After treatment for 72 h, genomic DNA was extracted from the 
cells using a QIAamp DNA Mini Kit (Qiagen). Sodium bisulfite conversion 
of 200 ng of the purified DNA was performed using an EpiTect Bisulfite 
Kit (Qiagen) according to the manufacturer’s protocol. MSP of bisulfate-
converted DNA was carried out in a nested, two-stage PCR approach as 
described previously (22) using GeneAmp PCR System 2700 (Applied 
Biosystems, Grand Island, NY). U87 and U138 cell lines were used as 
methylated and unmethylated controls, respectively. Amplified PCR prod-
ucts were separated by 3% agarose gel electrophoresis and visualized with 
ethidium bromide.
MethyLight assay
T98G, U251 and U138 cells were serum starved for 24 h and then treated 
with DMSO (control) or escalating concentrations of AR-A014418 (5, 10 
or 20 μmol/l) dissolved in equivalent amount of DMSO or combination of 
DMSO–AR-A014418 (5, 10 or 20 μmol/l) and c-Myc inhibitor 20 μmol/l. 
After treatment for 72 h, genomic DNA was extracted from the cells using 
a QIAamp DNA Mini Kit and subjected to bisulfite conversion using an 
EpiTect Bisulfite Kit followed by quantitative real-time PCR (qPCR) of 
bisulfite-converted DNA using PCR premix TaKaRa ExTaq (TaKaRa, Otsu, 
Japan) with primers and probe specific to methylated fraction of the MGMT 
promoter. Probe and forward primer sequences were taken from other study 
(23): probe, 6FAM-CCTTACCTCTAAATACCAACCCCAAACCCG-BHQ-1; 
forward primer, 5′-CTAACGTATAACGAAAATCGTAACAACC-3′; reverse 
primer designed by authors, 5′-AGTATGGAAGGGTAGGAAGAATTCG-3′. 
Alu was utilized as a calibrator (24) with following probe and prim-
ers: probe, 6FAM-CCTACCTTAACCTCCC-BHQ-1; forward primer, 
5′-GGTTAGGTATAGTGGTTTATATTTGTAATTTTAGTA-3′; reverse primer, 
5′-ATTAACTAAACTAATCTTAAACTCCTAACCTCA-3′. The qPCR was 
performed using LightCycler 1.5 (Roche Diagnostics GmbH, Mannheim, 
Germany) with protocol consisting of an initial denaturation step at 95°C for 
30 s followed by 40 cycles of 95°C for 15 s and 60°C for 60 s. LightCycler 
Software 4.1 was used to analyze the qPCR data. Threshold cycle values (Ct) 
were determined and relative methylation of the MGMT promoter was cal-
culated using the ΔCT method described by the manufacturer using Alu as a 
calibrator gene.
Real-time quantitative reverse transcriptase–polymerase chain reaction
T98G, U251 and U138 cells were serum starved for 24 h and then treated with 
DMSO (control) or escalating concentrations of AR-A014418 (5, 10 or 20 μmol/l) 
dissolved in equivalent amount of DMSO. After treatment for 72 h, total RNA 
was isolated from the cells using a GenElute Mammalian Total RNA Miniprep 
Kit (Sigma). Complementary DNA was synthesized from total RNA using a High 
phosphorylation of GS is found in the cells of primary tumors (arrows), whereas faint staining is observed in the recurrent tumors obtained at autopsy. Cell nuclei 
were counterstained with hematoxylin. Scale bars, 50 μm. (B) The immunohistochemical expression of MGMT protein in the tumor tissues. a and b, patient 
1; c and d, patient 2; a and c, primary tumor; b and d, the GSK3β-inhibiting drug-treated recurrent tumor obtained at autopsy. Cells with nuclear staining were 
considered as positive for MGMT expression (arrows). Cell nuclei were counterstained with hematoxylin. Scale bars, 50 μm. (C) Staining intensity of glioma 
cells was scored individually for MGMT antibody in each specimen and was classified as no (0), weak (1), moderate (2) or strong staining (3); mean staining 
intensity was calculated separately for primary specimen and autopsy specimen in patients 1 and 2. (D) MSP assay for methylation status of the MGMT promoter 
in GBM cells and the primary and recurrent tumors of the patients. PCR products in the M lanes and U lanes indicate methylated and unmethylated status of the 
MGMT promoter, respectively. U138, U138 GBM cell line as an unmethylated control; U87, U87 GBM cell line as a methylated control. The representative case 
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Fig. 2. (A) A comparison of the levels of MGMT gene expression in T98G, U138, U251 and U87 GBM cells by QRT–PCR with primers specific to MGMT. The 
relative value of MGMT messenger RNA expression in T98G was scored as 1.0. *BLQ, below the limit of quantitation; bars show standard deviations in the data. 
The figure shows the data from three independent experiments. (B) The effect of GSK3β–RNA interference on GBM cell survival. Values of relative cell viability 
were measured by the AlamarBlue assay and compared between T98G and U251 cells transfected with GSK3β-specific and non-specific siRNA (10 nmol/l 
each), respectively, for 72 h. The relative viability of the cells treated with non-specific siRNA was scored as 1.0. *P = 0.002; Mann–Whitney U-test, bars show 
standard deviation. The figure shows the data from experiments carried out in sextuplicates. (C and D) The relative cell viability of T98G and U251 cells was 
measured by the AlamarBlue assay and compared between cells treated with DMSO (control) or AR-A014418 (5, 10, 20, 40 or 80 μmol/l) for 144 h. The relative 
viability of the cells treated with DMSO was scored as 1.0. *P < 0.05; Mann–Whitney U-test, bars show standard deviation. The figure shows the data from 
experiments carried out in sextuplicates. (E) The effect of GSK3β inhibitor (AR-A014418) on the expression of total and tyrosine 216-phosphorylated GSK3β. 
Equal amounts of whole-cell lysates from T98G, U138, U251 and U87 cells treated with DMSO or 20 μmol/l AR-A014418, respectively, for 72 h were analyzed 
by western blot of total and phosphorylated GSK3β proteins, with β-actin used as loading control. AR, AR-A014418. The figure shows the representative data 












Fig.  3. The combined effect of TMZ and a GSK3β inhibitor (AR-A014418) on GBM cells. (A) The relative cell viability of T98G cells after treatment for 
144 h with TMZ (50, 100, 200 and 400 μmol/l) or AR-A014418 (5, 10 and 20 μmol/l), alone or in different combinations shown below the panel, measured 
by the AlamarBlue assay. The relative viability of the cells treated with DMSO alone was scored as 1.0. *P  < 0.05, **P  < 0.01, AR, AR-A014418; Mann–
Whitney U-test, compared with DMSO-treated cells; bars show standard deviation. (B–G) A  comparison of combined effect of TMZ (50, 100, 200 and 
400 μmol/l) and AR-A014418 (5, 10 and 20 μmol/l) on T98G, U138 and U87 cells. (B–D) Classic isobologram method. The IC50 values of the combination 
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Capacity complementary DNA Reverse Transcription Kit (Applied Biosystems). 
Quantitative reverse transcriptase–polymerase chain reaction (QRT–PCR) was 
performed using a LightCycler FastStart DNA MasterPlus SYBRGreen kit 
(Roche Diagnostics GmbH) with the respective sense and antisense primers for 
MGMT and glyceraldehyde 3-phosphate dehydrogenase (all from Sigma) that 
span exon–exon junctions preventing amplification of contaminating genomic 
DNA. QRT–PCR was carried out in a LightCycler 1.5 as described previously 
(25). QRT–PCR was done with the following set of primers for MGMT 
(NM_002412.3): forward primer, 5′-CCTGGCTGAATGCCTATTTC-3′ and 
reverse primer, 5′-TGTCTGGTGAACGACTCTTG-3′ (amplicon size: 100 
bp); and for glyceraldehyde 3-phosphate dehydrogenase (NM_002046.3): 
forward primer, 5′-CTCCTCCTGTTCGACAGTCA-3′ and reverse primer, 
5′-CCAATACGACCAAATCCGTTG-3′ (amplicon size: 112 bp). All primers 
other than the MGMT forward primer (26) were designed with Primer-
BLAST software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The 
QRT–PCR reaction protocol consisted of an initial denaturation step at 95°C 
for 10 min followed by 40 cycles of 95°C for 10 s, 60°C for 10 s and 72°C for 
5 s. LightCycler Software 4.1 was used to analyze the QRT–PCR data. Ct was 
determined and relative messenger RNA expression was calculated using the 
ΔCT method described by the manufacturer using glyceraldehyde 3-phosphate 
dehydrogenase as a calibrator gene.
Chromatin immunoprecipitation assay
To assess c-Myc and DNA (cytosine-5)-methyltransferase 3A (DNMT3A) 
binding to the MGMT promoter chromatin immunoprecipitation (ChIP) assay 
was performed utilizing a SimpleChIP Enzymatic Chromatin IP Kit (Cell 
Signaling Technology) as described previously (27). Briefly, two-step protein 
and chromatin fixation was performed with N-hydroxysuccinimide ester-
ester cross-linking reagent ethylene glycol bis(succinimidylsuccinate) (EGS) 
(Pierce Biotechnology, Rockford, IL) and formaldehyde (Sigma). EGS stock 
solution was added to T98G and U138 cells to a final concentration of 2 mM 
and rapidly mixed. Cells were fixed with EGS for 45 min at room temperature. 
After EGS fixation, the cells were washed three times with phosphate-buffered 
saline. Ten milliliters of a freshly prepared 1% (v/v) solution of formalde-
hyde in phosphate-buffered saline, pH 8.0, were added, and the cells were 
incubated at room temperature for 15 min and processed according to the 
SimpleChIP Enzymatic Chromatin IP Kit protocol. We used anti-c-Myc (Cell 
Signaling Technology), anti-DNMT3A antibodies (Imgenex) and anti-histone 
H3 (D2B12) XP antibody (Cell Signaling Technology) as a positive control 
or anti-FLAG M2 antibody (Sigma) as an unrelated antibody as a negative 
control. Immunoprecipitated DNA was analyzed by qPCR using LightCycler 
1.5 with a LightCycler FastStart DNA MasterPlus SYBRGreen kit and the 
primers for E-box localized in the human MGMT promoter (NT_008818.16 
2498978-83). We designed these primers and tested their specificity with 
Primer-BLAST software. Sequences of the primers used are available on 
request. The LightCycler Software 4.1 was used to evaluate the qPCR data. Ct 
were determined and % input values were calculated.
Statistical analyses
Statistical analyses were done using Mann–Whitney U-test and Kruskal–
Wallis one-way analysis of variance test. P < 0.05 was considered significant.
Results
Inhibition of glycogen synthase phosphorylation by 
GSK3β-inhibiting drugs
To assess the effect of the GSK3β-inhibiting drugs in the patients 
with recurrent GBM, immunohistochemistry was performed on tumor 
specimens. The primary tumor and the recurrent tumor tissues in all 
patients were positive for glycogen synthase (GS) (Supplementary 
Figure S1, available at Carcinogenesis Online). Phosphorylation of 
GS reflects GSK3β activity since GS is the primary substrate for 
GSK3β (8). Immunohistochemistry demonstrated that the cytoplasm 
of tumor cells was strongly positive for p-GSS641 in patients 1 and 
2 (Figure 1A, a and c). However, staining was weak in the tumors 
obtained by autopsy (Figure 1A, b and d). In contrast, p-GSS641 was 
preserved in autopsy specimen in patient 3 (Supplementary Figure 
S2, available at Carcinogenesis Online). This result suggests that the 
GSK3β-inhibiting drugs function in the tumor cells of the patients.
Changes in the expression and promoter methylation of MGMT in 
the tumors
The level of MGMT expression was compared by immunohistochem-
istry of the primary tumor and the recurrent tumor tissues from the 
same patients treated with the GSK3β-inhibiting drugs (Figure  1B 
and C). Tumor cells were strongly positive for MGMT in primary 
tumors (Figure 1B, a and c), whereas weak expression was observed 
in the tumors obtained at autopsy in patients 1 and 2, respectively 
(Figure 1B, b and d). In contrast, MGMT was detected both in pri-
mary tumor and autopsy specimen in patient 3 (Supplementary Figure 
S3, available at Carcinogenesis Online). This suggests that MGMT 
was downregulated in response to the inhibition of GSK3β in the 
tumor tissues.
With the findings shown above, we hypothesized that treatment 
with the GSK3β-inhibiting drugs decreased MGMT expression in the 
tumors by epigenetic silencing of its gene. To address this, a MSP 
assay was performed to examine the methylation status of the MGMT 
promoter in the tumor tissues. Although the MGMT promoter was 
unmethylated in the primary tumors at surgery, it became methylated 
in the tumors obtained at autopsy in patient 1 (Figure 1D).
MGMT gene expression in glioma cells
We investigated the mechanism of MGMT silencing by GSK3β inhi-
bition. Initially, we screened for the glioma cell lines T98G, U138, 
U251 and U87. Basal MGMT gene expression was determined by 
QRT–PCR. T98G, U138 and U251 cell lines expressed the MGMT 
gene transcripts, whereas U87 showed no detectable MGMT gene 
expression (Figure 2A).
GSK3β inhibition and glioma cell viability
To determine the function of GSK3β in the glioma cell lines, we 
used siRNA to specifically knockdown endogenous GSK3β. The 
specific reduction of GSK3β by siRNA was determined in our pre-
vious study (10). Depletion of GSK3β, confirmed by western blot 
analysis (Supplementary Figure S4, available at Carcinogenesis 
Online), significantly decreased cell viability in T98G and U251 
cells (Figure 2B). To further assess the effect of inhibition of GSK3β 
activity, we treated the cells with dose-escalating AR-A014418. 
Cell viability was decreased by AR-A014418 treatment in a dose-
dependent manner in T98G cells (Figure 2C). IC50 was ~20 μmol/l. 
Decreased viability by AR-014418 was also observed in U251 cells 
(Figure 2D). Consistently with previous study showing depletion of 
GSK3β by AR-A014418 treatment (28), depletion of total and tyros-
ine 216-phosphorylated GSK3β by AR-A014418 was observed in 
glioma cells by western blot analysis (Figure 2E). These data showed 
that GSK3β inhibition attenuates viability in T98G and U251 cells. 
According to the range of linear dose-dependent response in T98G 
cells, a 5–20 μmol/l dose range of AR-A014418 was used to assess 
combination treatment with TMZ.
Combined effect of GSK3β inhibitor and TMZ in GBM cells
To investigate whether GSK3β inhibition enhances TMZ effect, 
T98G, U138 and U87 cells were treated with different doses of 
TMZ or AR-A014418, alone or in combination. Compared with 
U138, U87 (Supplementary Figure S5, available at Carcinogenesis 
Online) and U251 as shown previously (10), T98G cells were much 
A 5 and 10 μmol/l of AR-A014418 and 50 and 200 μmol/l of TMZ appeared to be under the envelope of additivity (continuous line with closed square and 
continuous line with closed circle, respectively), showing synergistic action against T98G cells. IC50 values for combination treatment, which are inside the 
envelope of additivity, reveal the additive action of TMZ and AR-A014418 treatment against GBM cells. (E–G) Median dose-effect analysis. Dose-normalized 
combination indices (CI) of the combination therapy by TMZ and AR-A014418 were plotted. CI values for combination treatment within intervals 0.3–0.7, 
0.7–0.85, 0.85–0.90 and 0.90–1.10 reveal synergism, moderate synergism, slight synergism and nearly additive action, respectively, of TMZ and AR-A014418 













Fig. 4. (A) Changes in MGMT gene methylation status in GBM cells by GSK3β inhibition. The effect of GSK3β inhibition with 5, 10 or 20 μmol/l of 
AR-A014418 for 72 h on the methylation status of the MGMT promoter in T98G, U251 and 138 cells was observed by MSP assay. PCR products in the M lanes 
and U lanes indicate methylated and unmethylated status of the MGMT promoter, respectively. U87, U87 GBM cell line as a methylated control; U138, U138 
GBM cell line as an unmethylated control; AR, AR-A014418. (B) The effect of GSK3β inhibition on methylation status of the MGMT promoter examined with 
MethyLight assay in T98G, U251 and U138 cells treated for 72 h with DMSO or AR-A014418 (5, 10 or 20 μmol/l). qPCR of bisulfite-converted DNA with the 
primers and probes specific to the methylated fraction of the MGMT promoter. The level of MGMT promoter methylation in the cells treated with DMSO was 
scored as 1.0. *P < 0.05, **P < 0.01, AR, AR-A014418; Mann–Whitney U-test, bars show standard deviation. The figure shows the data from three independent 
experiments. (C) QRT–PCR analysis of the effect of GSK3β inhibition on MGMT gene expression in T98G, U251 and U138 cells treated with DMSO or 
AR-A014418 (5, 10 or 20 μmol/l), respectively, for 72 h. The level of MGMT messenger RNA expression in the cells treated with DMSO was scored as 1.0. *BLQ, 
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Fig. 5. (A) The effect of GSK3β inhibitor (AR-A014418) on the expression of MGMT and c-Myc. Equal amounts of whole-cell lysates from T98G, U138 and 
U251 cells treated with DMSO or 20 μmol/l AR-A014418, respectively, for 72 h were analyzed by western blot of c-Myc and MGMT proteins, with β-actin used as 
loading control, AR, AR-A014418. The figure shows the representative data from three independent western blots. (B) Changes in MGMT gene methylation status in 
GBM cells by GSK3β and c-Myc inhibition. The effect of combination of DMSO–AR-A014418 (5, 10 or 20 μmol/l) and c-Myc inhibitor 20 μmol/l for 72 h on the 
methylation status of the MGMT promoter in T98G, U251 and U138 cells was observed by MSP assay. PCR products in the M lanes and U lanes indicate methylated 
and unmethylated status of the MGMT promoter, respectively. U87, U87 GBM cell line as a methylated control; U138, U138 GBM cell line as an unmethylated 
control; AR, AR-A014418. (C) The effect of GSK3β and c-Myc inhibition on methylation status of the MGMT promoter examined with MethyLight assay in T98G, 
U251 and U138 cells treated for 72 h with combination of DMSO–AR-A014418 (5, 10 or 20 μmol/l) and c-Myc inhibitor 20 μmol/l. qPCR of bisulfite-converted DNA 
with the primers and probes specific to the methylated fraction of the MGMT promoter. The level of MGMT promoter methylation in the cells treated with DMSO was 












Fig. 6. Epigenetic silencing of MGMT expression by GSK3β inhibition. (A and B) Comparison by ChIP assay of the binding of histone H3, c-Myc, DNMT3A 
and FLAG to the E-box site in the MGMT promoter between the GBM cells treated with DMSO or with a GSK3β inhibitor (AR-A014418). T98G and U138 
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more chemoresistant to TMZ (Figure 3A), which is consistent with 
a higher basal level of MGMT expression (Figure 2A). The combi-
nation of low-dose AR-A014418 and TMZ significantly reduced 
cell viability compared with the treatment with TMZ or low-dose 
AR-A014418 alone (Figure  3A). Classic isobologram analysis and 
median dose-effect analysis were performed to evaluate whether low-
dose AR-A014418 potentiates TMZ effect against GBM cells. The 
data obtained showed mainly synergistic antitumor effect of low-dose 
AR-A014418 (5, 10 and 20 μmol/l) in combination with TMZ in 
T98G cells (Figure 3B and E), whereas U138 demonstrating lower 
basal MGMT expression (Figure 2A) showed additive and moderate 
synergistic effect (Figure 3C and F), while mainly additive effect was 
noted in U87 (Figure 3D and G) and in U251 in our previous report 
(10) with undetectable and low MGMT expression, respectively 
(Figure 2A).
Effect of GSK3β inhibition on MGMT promoter methylation status 
and gene expression
To investigate the influence of GSK3β inhibition on MGMT pro-
moter methylation, a MSP assay was performed in T98G, U251 
and U138 cells expressing MGMT (Figure 2A). AR-A014418 treat-
ment decreased or ablated unmethylated MGMT promoter in T98G, 
increased methylated MGMT promoter in U251 and decreased 
unmethylated MGMT promoter in U138 cells revealing methylated 
MGMT promoter at 20 μmol/l (Figure  4A). MSP assay data were 
confirmed by the MethyLight assay showing that GSK3β inhibi-
tion increased methylation of CpG islands in the MGMT promoter 
in T98G, U251 and U138 cells after treatment with AR-A014418 
(Figure  4B). Consistent with the changes in methylation levels, 
GSK3β inhibition by AR-A014418 decreased the levels of MGMT 
gene expression in T98G, U138 and U251 cells as measured by 
QRT–PCR (Figure 4C). Consistently, MGMT protein expression was 
decreased by AR-A014418 treatment in T98G and U138, whereas 
MGMT was undetectable in U251 cells with low MGMT expression 
(Figures 2A and 5A).
Effect of GSK3β inhibition on c-Myc and DNMT3A binding to the 
MGMT promoter
To investigate the molecules that are responsible for the changes in 
MGMT promoter methylation status, we focused on c-Myc signaling. 
c-Myc is a good candidate since GSK3β inhibition increases c-Myc 
expression in U251 (12), T98G, U138 (Figure 5A and Supplementary 
Figure S6, available at Carcinogenesis Online) and U87 cells 
(I.V.Pyko, unpublished results), as shown by western blot analysis 
and QRT–PCR (I.V.Pyko, unpublished results).
To determine if the effect of GSK3β inhibition on MGMT pro-
moter methylation is mediated by c-Myc signaling, we performed 
MSP assay and MethyLight assay in T98G, U251 and U138 cell 
lines treated with combination of DMSO–AR-A014418 and c-Myc 
inhibitor. As shown in Figure  5B, the c-Myc inhibitor caused 
increase/appearance of unmethylated MGMT promoter in T98G 
and U251 cells and ablated AR-A014418-induced MGMT promoter 
methylation (Figure 4A) in U138 cells in MSP assay, suggesting that 
c-Myc plays a role in MGMT promoter methylation in the GBM 
cells. Comparing with the data shown in Figure  4A, concomitant 
treatment with the c-Myc inhibitor and AR-A014418 maintained 
the fraction of unmethylated MGMT promoter in these cells. 
MethyLight assay demonstrated that c-Myc inhibitor abrogated the 
AR-A014418-induced increase of MGMT promoter methylation in 
all cells (Figure  5C). The results of MSP and MethyLight assays 
collectively suggest that c-Myc-mediated signaling is responsible 
for MGMT promoter methylation induced by the GSK3β inhibitor 
in the GBM cells.
c-Myc is a target for β-catenin-mediated gene transcription by 
T-cell factor/lymphoid-enhancer factor (29). We have shown previ-
ously that GSK3β inhibition increases β-catenin expression in T98G 
and U251 cells (10). To determine if c-Myc expression is increased via 
β-catenin signaling in the glioma cell lines, we used siRNA to specifi-
cally knockdown endogenous β-catenin. Depletion of β-catenin, con-
firmed by western blot analysis (Supplementary Figure S7, available 
at Carcinogenesis Online), resulted in decreased c-Myc expression 
in U138; however, in T98G and U251, β-catenin depletion increased 
c-Myc expression and produced no significant changes in U87 cells 
(Supplementary Figure S7, available at Carcinogenesis Online). It 
suggests that the regulation of c-Myc by β-catenin under GSK3β inhi-
bition is cell dependent.
c-Myc is known to selectively target DNMT3A to the promoter 
of the gene, resulting in DNA methylation de novo and silencing of 
the targeted promoter (30). DNMT3A protein expression was not 
changed by GSK3β siRNA (Supplementary Figure S8, available at 
Carcinogenesis Online), suggesting that changes in DNMT3A expres-
sion are not involved in regulation of MGMT promoter methylation 
via DNMT3A in GBM cells.
We examined possible interaction between c-Myc and DNMT3A 
by the ChIP assay. We chose T98G and U138 cells since T98G is 
highly resistant to TMZ due to the high basal level of MGMT gene 
expression (Figure 2A), and the observed synergistic effect of com-
bined treatment with AR-A014418 and TMZ against T98G and 
U138 cells (Figure 3B, C, E and F) was accompanied by a decrease 
in unmethylated MGMT promoter after AR-A014418 treatment 
(Figure 4A). In ChIP assay, c-Myc binding to the E-box transcription 
factor-binding site in the MGMT promoter was on detectable level in 
U138 and below the limit of quantitation in T98G in DMSO-treated 
control, whereas AR-A014418 treatment increased c-Myc binding to 
the same site in the MGMT promoter in both cell lines. This find-
ing was accompanied by increased DNMT3A binding to the same 
region in the MGMT promoter in T98G and U138 cells (Figure 6A 
and B). These data suggest that, in response to GSK3β inhibition, 
c-Myc recruits DNMT3A to the MGMT promoter, which increases 
its methylation level in T98G and U138 cells.
Discussion
In our clinical research, the GSK3β-inhibiting drugs inhibited GS 
phosphorylation and decreased MGMT expression, a predictor for 
resistance to TMZ, in tumor cells in patients with recurrent GBM. 
Consistent with these findings, the status of the MGMT promoter 
changed from unmethylated to methylated after treatment with 
GSK3β-inhibiting drugs. These data suggest that GSK3β inhibi-
tion decreases MGMT production in GBM affecting the methylation 
status of the MGMT promoter. This observation in patient tumors 
was extrapolated by novel findings in this study, demonstrating that 
GSK3β inhibition in GBM cells induced c-Myc-dependent recruit-
ment of DNMT3A, leading to MGMT promoter methylation and con-
sequent silencing of MGMT expression (Figure 6A and B).
In our study, T98G and U138 cells appeared to be highly resist-
ant to TMZ treatment, and this can be attributed to high MGMT 
gene expression level in these cell lines. It is consistent with previ-
ous reports asserting that T98G has the highest MGMT expression 
level among 10 GBM cell lines (7) and is extremely resistant to TMZ 
(31,32). Here, we showed that GSK3β inhibition enhanced TMZ 
effect in T98G cells to sensitivity levels seen in TMZ-sensitive cell 
lines (10). The synergistic effect observed for the combination treat-
ment of GSK3β inhibitor with low-dose TMZ (50 μmol/l) may be 
considered in future clinical applications as it is within the TMZ ther-
apeutic window for systemic administration (33,34).
qPCR with a set of primers specific to the E-box transcription factor-binding site in the MGMT promoter. *BLQ, below the limit of quantitation. The figure shows 
the representative data from two independent immunoprecipitations. (C) Regulation of MGMT expression by GSK3β signaling. GSK3β inhibition results in c-Myc 
activation directly and via activation of β-catenin-mediated signaling, which consequently increases recruitment of DNMT3A by c-Myc to the MGMT promoter, 













c-Myc is an important factor in cell proliferation that enables G1/S 
cell cycle progression (35). Despite its role in cell proliferation, several 
studies show an essential role for c-Myc in apoptosis (36,37). A previ-
ous report demonstrated that c-Myc has a suppressive effect in human 
GBM cells, as c-Myc upregulation is associated with increased apop-
tosis (12). GSK3β has also been reported to phosphorylate (38) and 
destabilize c-Myc (11) and GSK3β inhibition in glioma cells along 
with the upregulation of Ser62 phosphorylation and downregulation of 
Thr58 phosphorylation of c-Myc, results in increased c-Myc expres-
sion (12). Taken together, c-Myc expression is increased in GBM cells 
by GSK3β inhibition via its effects on c-Myc phosphorylation and in 
some cell lines its effect on β-catenin mediated gene transcription.
Considering the role of c-Myc in apoptosis (12), additive effect of 
GSK3β inhibition and TMZ in U87 showing undetectable MGMT 
expression (Figure 3D and G) can be explained by c-Myc upregula-
tion (I.V.Pyko, unpublished results). Moreover, TMZ induces G2/M 
arrest decreasing its effect (39) by retention of proliferative capacity 
in U87 cells (40). Accordingly, our laboratory previously have shown 
cyclin D1 upregulation in U87 by GSK3β inhibition (10), suggesting 
that GSK3β inhibition can enhance TMZ effect in U87 cells reducing 
TMZ-induced G2/M arrest.
It is known that c-Myc can silence gene expression by active 
recruitment of corepressor proteins and that it can target DNMT3A 
selectively to the promoter of the gene (30). However, there are no 
studies showing binding of c-Myc to the MGMT promoter (41), 
despite the presence of an E-box transcription factor-binding site 
in the MGMT promoter. In this study, we hypothesized that a high 
expression level of c-Myc in GBM cells induced by GSK3β inhibi-
tion induces c-Myc binding to the E-box, resulting in transcriptional 
repression via recruitment of DNMT3A.
Our ChIP assay demonstrated for the first time that c-Myc binds 
to the MGMT promoter in intact cells and that c-Myc and DNMT3A 
binding to the MGMT promoter increases after AR-A014418 treat-
ment. The mediation of c-Myc for recruitment of DNMT3A to 
the MGMT promoter was confirmed by comparison of data from 
the conventional ChIP assay, which includes a one-step protein 
and chromatin fixation with formaldehyde (I.V.Pyko, unpublished 
results) and data from the ChIP assay with a two-step protein and 
chromatin fixation shown in this study. Conventional ChIP assay, 
which effectively detects direct protein–DNA binding, did not reveal 
detectable DNMT3A binding to the MGMT promoter. In contrast, 
ChIP assay with a two-step protein and chromatin fixation provides 
effective detection of both direct protein–DNA binding and indirect 
protein–protein–DNA binding (27). Consequently, our ChIP assay 
with a two-step protein and chromatin fixation showed detectable 
DNMT3A binding to the MGMT promoter with an increased binding 
level in GBM cells treated with AR-A014418. This was consistent 
with an increase in c-Myc binding after AR-A014418 treatment, sug-
gesting recruitment of DNMT3A by c-Myc to the MGMT promoter 
(Figure 6A and B).
Based on our data, we speculate that GSK3β inhibition eliminates 
the suppressive effect of GSK3β on c-Myc expression by the effects 
on c-Myc phosphorylation, which subsequently increases recruit-
ment of DNMT3A by c-Myc to the MGMT promoter in GBM cells. 
The interaction between c-Myc and DNMT3A would then acti-
vate DNA methyltransferase, which increases local de novo DNA 
methylation in the CpG islands of the MGMT promoter. MGMT 
promoter methylation silences MGMT gene expression, and this 
finally sensitizes GBM cells to TMZ (Figure  6C). The provided 
data will facilitate the development of an optimal combination of 
GSK3β inhibitor and alkylating agents for their use in the treatment 
of patients with GBM. Further in vivo research is needed to optimize 
combination regimens of TMZ and GSK3β inhibitor for the treat-
ment of refractory GBM.
Supplementary material
Supplementary Figures S1–S8 can be found at http://carcin.oxford-
journals.org/
Funding
Grant-in-Aid for Scientific Research from the Japan Society for 
the Promotion of Science (C-23592117 to M.N.); Foundation for 
Promotion of Cancer Research to M.N.; Kobayashi Foundation for 
Cancer Research to M.N.
Conflict of Interest Statement: None declared.
References
 1. DeAngelis,L.M. (2001) Brain tumors. N. Engl. J. Med., 344, 114–123.
 2. Lefranc,F. et al. (2005) Possible future issues in the treatment of glioblas-
tomas: special emphasis on cell migration and the resistance of migrating 
glioblastoma cells to apoptosis. J. Clin. Oncol., 23, 2411–2422.
 3. Stewart,L.A. (2002) Chemotherapy in adult high-grade glioma: a sys-
tematic review and meta-analysis of individual patient data from 12 ran-
domised trials. Lancet, 359, 1011–1018.
 4. Miyashita,K. et al. (2009) An emerging strategy for cancer treatment tar-
geting aberrant glycogen synthase kinase 3 beta. Anticancer. Agents Med. 
Chem., 9, 1114–1122.
 5. Nakada,M. et  al. (2011) The pivotal role of GSK3β in glioma biology. 
In Garami,M. (ed.) Molecular Targets of CNS Tumors. InTech, Croatia, 
pp. 567–590.
 6. Hegi,M.E. et al. (2005) MGMT gene silencing and benefit from temozolo-
mide in glioblastoma. N. Engl. J. Med., 352, 997–1003.
 7. Costello,J.F. et al. (1994) Graded methylation in the promoter and body of 
the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with 
MGMT expression in human glioma cells. J. Biol. Chem., 269, 17228–17237.
 8. Jope,R.S. et  al. (2004) The glamour and gloom of glycogen synthase 
kinase-3. Trends Biochem. Sci., 29, 95–102.
 9. Bhat,R. et  al. (2003) Structural insights and biological effects of glyco-
gen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem., 278, 
45937–45945.
 10. Miyashita,K. et al. (2009) Potential therapeutic effect of glycogen synthase 
kinase 3 beta inhibition against human glioblastoma. Clin. Cancer Res., 15, 
887–897.
 11. Gregory,M.A. et al. (2003) Phosphorylation by glycogen synthase kinase-3 
controls c-myc proteolysis and subnuclear localization. J. Biol. Chem., 278, 
51606–51612.
 12. Kotliarova,S. et al. (2008) Glycogen synthase kinase-3 inhibition induces 
glioma cell death through c-MYC, nuclear factor-kappaB, and glucose 
regulation. Cancer Res., 68, 6643–6651.
 13. Louis,D.N. et al. (2007) The 2007 WHO classification of tumours of the 
central nervous system. Acta Neuropathol., 114, 97–109.
 14. Yoshida,Y. et al. (2010) Sphingosine-1-phosphate receptor type 1 regulates 
glioma cell proliferation and correlates with patient survival. Int. J. Cancer, 
126, 2341–2352.
 15. Wauthoz,N. et al. (2010) In vivo assessment of temozolomide local deliv-
ery for lung cancer inhalation therapy. Eur. J. Pharm. Sci., 39, 402–411.
 16. Nakada,M. et  al. (2005) EphB2/R-Ras signaling regulates glioma cell 
adhesion, growth, and invasion. Am. J. Pathol., 167, 565–576.
 17. Breinholt,V. et al. (1998) Detection of weak estrogenic flavonoids using 
a recombinant yeast strain and a modified MCF7 cell proliferation assay. 
Chem. Res. Toxicol., 11, 622–629.
 18. Steel,G.G. et al. (1979) Exploitable mechanisms in combined radiother-
apy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. 
Phys., 5, 85–91.
 19. Chou,T.C. et al. (1984) Quantitative analysis of dose-effect relationships: 
the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme 
Regul., 22, 27–55.
 20. Chou,T.C. (2006) Theoretical basis, experimental design, and computer-
ized simulation of synergism and antagonism in drug combination studies. 
Pharmacol. Rev., 58, 621–681.
 21. Palmisano,W.A. et al. (2000) Predicting lung cancer by detecting aberrant 
promoter methylation in sputum. Cancer Res., 60, 5954–5958.
 22. Suzuki,T. et al. (2011) The correlation between promoter methylation sta-
tus and the expression level of O6-methylguanine-DNA methyltransferase 
in recurrent glioma. Jpn. J. Clin. Oncol., 41, 190–196.
 23. Eads,C.A. et al. (2001) Epigenetic patterns in the progression of esopha-
geal adenocarcinoma. Cancer Res., 61, 3410–3418.
 24. Weisenberger,D.J. et al. (2005) Analysis of repetitive element DNA meth-
ylation by MethyLight. Nucleic Acids Res., 33, 6823–6836.
 25. Mariani,L. et al. (2001) Identification and validation of P311 as a glioblas-












GSK3β inhibition enhances TMZ sensitivity
 26. Rolhion,C. et al. (1999) O(6)-methylguanine-DNA methyltransferase gene 
(MGMT) expression in human glioblastomas in relation to patient charac-
teristics and p53 accumulation. Int. J. Cancer, 84, 416–420.
 27. Nowak,D.E. et  al. (2005) Two-step cross-linking method for identifica-
tion of NF-kappaB gene network by chromatin immunoprecipitation. 
Biotechniques, 39, 715–725.
 28. Bilim,V. et al. (2009) Glycogen synthase kinase-3: a new therapeutic target 
in renal cell carcinoma. Br. J. Cancer, 101, 2005–2014.
 29. Baek,S.H. et al. (2003) Regulated subset of G1 growth-control genes in 
response to derepression by the Wnt pathway. Proc. Natl Acad. Sci. USA, 
100, 3245–3250.
 30. Brenner,C. et al. (2005) Myc represses transcription through recruitment of 
DNA methyltransferase corepressor. EMBO J., 24, 336–346.
 31. Kanzawa,T. et al. (2003) Inhibition of DNA repair for sensitizing resistant 
glioma cells to temozolomide. J. Neurosurg., 99, 1047–1052.
 32. Torres,S. et al. (2011) A combined preclinical therapy of cannabinoids and 
temozolomide against glioma. Mol. Cancer Ther., 10, 90–103.
 33. Ostermann,S. et al. (2004) Plasma and cerebrospinal fluid population phar-
macokinetics of temozolomide in malignant glioma patients. Clin. Cancer 
Res., 10, 3728–3736.
 34. Plummer,E.R. et al. (2005) Temozolomide pharmacodynamics in patients 
with metastatic melanoma: DNA damage and activity of repair enzymes 
O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. 
Clin. Cancer Res., 11, 3402–3409.
 35. Steiner,P. et al. (1995) Identification of a Myc-dependent step during the 
formation of active G1 cyclin-cdk complexes. EMBO J., 14, 4814–4826.
 36. Packham,G. et al. (1995) c-Myc and apoptosis. Biochim. Biophys. Acta, 
1242, 11–28.
 37. Askew,D.S. et  al. (1991) Constitutive c-myc expression in an IL-3-
dependent myeloid cell line suppresses cell cycle arrest and accelerates 
apoptosis. Oncogene, 6, 1915–1922.
 38. Pulverer,B.J. et al. (1994) Site-specific modulation of c-Myc cotransforma-
tion by residues phosphorylated in vivo. Oncogene, 9, 59–70.
 39. Hirose,Y. et al. (2001) Abrogation of the Chk1-mediated G(2) checkpoint 
pathway potentiates temozolomide-induced toxicity in a p53-independent 
manner in human glioblastoma cells. Cancer Res., 61, 5843–5849.
 40. Hirose,Y. et al. (2001) p53 effects both the duration of G2/M arrest and the 
fate of temozolomide-treated human glioblastoma cells. Cancer Res., 61, 
1957–1963.
 41. Zeller,K.I. et al. (2003) An integrated database of genes responsive to the 
Myc oncogenic transcription factor: identification of direct genomic tar-
gets. Genome Biol., 4, R69.





niversity Library on July 28, 2014
http://carcin.oxfordjournals.org/
D
ow
nloaded from
 
